21.94
-0.88(-3.86%)
Currency In HKD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1811
First IPO Date
June 30, 2021
| Name | Title | Pay | Year Born |
| Mr. Chig Fung Cheng BEc, CA | Acting Chief Executive Officer, Chief Financial Officer & Executive Director | 7.53M | 1967 |
| Dr. Wei-Guo Su B.Sc., Ph.D. | Chief Executive Officer, Chief Scientific Officer & Executive Director (Leave of Absence) | 16.95M | 1958 |
| Mr. Charles George Rupert Nixon | Group General Counsel | 0 | 1970 |
| Mr. Kin Hung Lee M.B.A. | Senior Vice President of Corporate Management & Communications | 0 | 1977 |
| David Ng | Head of Investor Relations & Capital Strategies | 0 | N/A |
| Ms. Yiling Cui | Executive Vice President & Head of Operations | 0 | N/A |
| Ms. Selina Zhang | Senior Vice President of Global Human Resources | 0 | N/A |
| Dr. Qingmei Wang Ph.D. | Executive Vice President of Business Development & Strategic Alliances | 0 | 1963 |
| Dr. Thomas Fu | Senior Vice President of Global Quality | 0 | N/A |
| Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E | Company Secretary & Non-Executive Director | 0 | 1952 |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.